Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 5,818 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EXTEND Clear all
Completed Phase 3 Interventional

Lesinurad and Allopurinol Combination Extension Study in Gout

NCT01808131
View directory record Official record
Conditions
Gout
Interventions
Lesinurad
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Pinson, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 17, 2026, 5:10 PM EDT
Enrolling by invitation Phase 3 Interventional

An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD

NCT07670702
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
TSND-201
Drug
Lead sponsor
Transcend Therapeutics
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Montclair, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

NCT00022672
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab (Herceptin®), anastrazole (Arimidex®)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00413777
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

NP2 Enkephalin For Treatment of Intractable Cancer Pain

NCT01291901
View directory record Official record
Conditions
Intractable Pain, Neoplasms
Interventions
NP2, Placebo
Biological
Lead sponsor
Diamyd Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Corona, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

NCT01630889
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03654274
View directory record Official record
Conditions
Endometriosis
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
60
States / cities
Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV

NCT04661813
View directory record Official record
Conditions
HIV-1-infection, Hypertension
Interventions
EXTRA-CVD Virtual Care
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

NCT00159874
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 17, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

NCT05312697
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Setrusumab
Biological
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
19 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 17, 2026, 5:10 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

NCT03898479
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 17, 2026, 5:10 PM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

NCT03319940
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Tarlatamab, Pembrolizumab, CRS Mitigation Strategies
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
15
States / cities
Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 17, 2026, 5:10 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg

NCT02712320
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
LMIS 50 mg
Drug
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Homewood, Alabama • San Diego, California • Meridian, Idaho + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 17, 2026, 5:10 PM EDT
Not listed Not applicable Interventional

Reading Remediation and Outcomes in Detention

NCT03261076
View directory record Official record
Conditions
Specific Learning Disorder (MeSH Unique ID: D000067559), Dyslexia (MeSH Unique ID: D004410), Conduct Disorder (MeSH Unique ID: D019955)
Interventions
Strategies Enhancing Reading in Older Underperf. Students
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Years to 16 Years · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 4 Interventional

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

NCT03229174
View directory record Official record
Conditions
Parkinson Disease, Neurogenic Orthostatic Hypotension
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

NCT00974974
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066, IR CD-LD
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

NCT01158079
View directory record Official record
Conditions
Solid Tumors
Interventions
ALN-VSP02
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 17, 2026, 5:10 PM EDT
Completed No phase listed Observational

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

NCT03709888
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Memantine XR-pregabalin combination therapy
Drug
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

NCT00891020
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
227
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 17, 2026, 5:10 PM EDT
Completed Not applicable Interventional

Prehabilitation for Pelvic Cancer: Changes in Setup Variability

NCT03242538
View directory record Official record
Conditions
Pelvic Cancer
Interventions
Pelvic Exercise
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 17, 2026, 5:10 PM EDT
Withdrawn Phase 4 Interventional

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

NCT02616315
View directory record Official record
Conditions
Weight Regain Post Bariatric Surgery
Interventions
Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 17, 2026, 5:10 PM EDT
Recruiting Phase 4 Interventional

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

NCT04781140
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
100mg SPN-812, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
48 Months to 69 Months
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
54
States / cities
Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 5:10 PM EDT
Active, not recruiting No phase listed Observational

Persona IQ Cohort Study

NCT06089291
View directory record Official record
Conditions
Osteo Arthritis Knee, Knee Arthritis, Monitoring Orthopedic Devices, Total Knee Arthroplasty, Total Knee Replacement
Interventions
Persona IQ
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Granger, Indiana • St Louis, Missouri • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 5:10 PM EDT